Identification

Name
Irbesartan
Accession Number
DB01029  (APRD00413)
Type
Small Molecule
Groups
Approved, Investigational
Description

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be associated with a small increased risk of cancer.

Structure
Thumb
Synonyms
  • 2-Butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
  • BMS 186295
  • Irbesartan
External IDs
BMS-186295 / SR 47436 / SR-47436
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act IrbesartanTablet300 mgOralActavis Pharma Company2011-03-21Not applicableCanada
Act IrbesartanTablet150 mgOralActavis Pharma Company2011-03-21Not applicableCanada
Act IrbesartanTablet75 mgOralActavis Pharma Company2011-03-21Not applicableCanada
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-irbesartanTablet75 mgOralApotex Corporation2012-09-25Not applicableCanada
Apo-irbesartanTablet150 mgOralApotex Corporation2012-09-25Not applicableCanada
Apo-irbesartanTablet300 mgOralApotex Corporation2012-09-25Not applicableCanada
IrbesartanTablet300 mg/1OralA S Medication Solutions2012-10-152017-06-20Us
IrbesartanTablet150 mg/1OralAjanta Pharma Limited2015-01-20Not applicableUs
IrbesartanTablet150 mg/1OralWest Ward Pharmaceutical2012-10-15Not applicableUs
IrbesartanTablet300 mg/1OralAurobindo Pharma2012-09-27Not applicableUs
IrbesartanTablet, coated75 mg/1OralWatson Pharmaceuticals2012-10-162016-10-13Us
IrbesartanTablet300 mg/1OralCamber Pharmaceuticals2012-09-27Not applicableUs
IrbesartanTablet75 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-02-24Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IrbesartanTablet75 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
IrbesartanTablet150 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
IrbesartanTablet300 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
Irbesartan BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
International/Other Brands
Avapro / Irbesarran / Lrbesartan
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Irbesartan/hctIrbesartan (300 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Pharma Company2011-03-21Not applicableCanada
Act Irbesartan/hctIrbesartan (150 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2011-03-21Not applicableCanada
Act Irbesartan/hctIrbesartan (300 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2011-03-21Not applicableCanada
Apo-irbesartan/hctzIrbesartan (150 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2013-02-26Not applicableCanada
Apo-irbesartan/hctzIrbesartan (300 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2013-03-26Not applicableCanada
Apo-irbesartan/hctzIrbesartan (300 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2013-02-26Not applicableCanada
Auro-irbesartan HctIrbesartan (300 mg) + Hydrochlorothiazide (25 mg)TabletOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-irbesartan HctIrbesartan (150 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-irbesartan HctIrbesartan (300 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAuro Pharma Inc2015-12-02Not applicableCanada
Ava-irbesartan/hctzIrbesartan (300 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAvanstra Inc2011-11-232014-08-21Canada
Categories
UNII
J0E2756Z7N
CAS number
138402-11-6
Weight
Average: 428.5294
Monoisotopic: 428.232459548
Chemical Formula
C25H28N6O
InChI Key
YOSHYTLCDANDAN-UHFFFAOYSA-N
InChI
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
IUPAC Name
2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
SMILES
CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

Pharmacology

Indication

For the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of congestive heart failure.

Structured Indications
Pharmacodynamics

Angiotensin II, the principal pressor agent of the renin-angiotensin system, is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. Irbesartan's inhibition of angiotensin II binding to the AT1 receptor leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.

Mechanism of action

Irbesartan is a nonpeptide tetrazole derivative and an angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor. In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II. Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. Irbesartan, by blocking the binding of angiotensin II to the AT1 receptor, promotes vasodilation and decreases the effects of aldosterone. The negative feedback regulation of angiotensin II on renin secretion is also inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin II plasma concentrations do not counteract the blood pressure–lowering effect that occurs. The action of ARBs is different from ACE inhibitors, which block the conversion of angiotensin I to angiotensin II, meaning that the production of angiotensin II is not completely inhibited, as the hormone can be formed via other enzymes. Also, unlike ACE inhibitors, irbesartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
UTranscription factor AP-1
other/unknown
Human
Absorption

Rapid and complete with an average absolute bioavailability of 60-80%. Food has no affect on bioavailability.

Volume of distribution
  • 53 to 93 L
Protein binding

90% bound to serum proteins (primarily albumin and a1-acid glycoprotein) with negligible binding to cellular components of blood.

Metabolism

Hepatic. Irbesartan is metabolized via glucuronide conjugation and oxidation. In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.

Route of elimination

Irbesartan is metabolized via glucuronide conjugation and oxidation. Irbesartan and its metabolites are excreted by both biliary and renal routes. Irbesartan is excreted in the milk of lactating rats.

Half life

11-15 hours

Clearance
  • 157-176 mL/min
Toxicity

Hypotension and tachycardia; bradycardia might also occur from overdose, LD50=mg/kg(orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Irbesartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Irbesartan.Experimental
AbirateroneThe serum concentration of Irbesartan can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Irbesartan.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Acemetacin.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Irbesartan.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Irbesartan.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Irbesartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Irbesartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Alminoprofen.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Irbesartan.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Irbesartan.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Irbesartan.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Irbesartan.Approved, Withdrawn
AmbrisentanIrbesartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineIrbesartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Irbesartan.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Irbesartan.Approved, Withdrawn
AmiodaroneThe metabolism of Irbesartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Irbesartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Irbesartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Irbesartan.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Irbesartan.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Irbesartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Irbesartan.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Irbesartan.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Irbesartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Irbesartan.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Irbesartan.Approved
ApocyninThe risk or severity of adverse effects can be increased when Irbesartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Irbesartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Irbesartan.Approved
ApremilastThe risk or severity of adverse effects can be increased when Irbesartan is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Irbesartan can be increased when combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Irbesartan.Experimental
ArdeparinArdeparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Irbesartan.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Irbesartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Irbesartan.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Irbesartan.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Irbesartan.Approved
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Irbesartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Irbesartan.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the antihypertensive activities of Irbesartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Irbesartan.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Irbesartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Irbesartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Irbesartan.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Irbesartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Irbesartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Irbesartan.Approved
BepridilIrbesartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Irbesartan.Investigational
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Irbesartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Irbesartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bevonium.Experimental
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Irbesartan.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Irbesartan.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Irbesartan.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Irbesartan.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Irbesartan.Approved, Investigational
BQ-123Irbesartan may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Irbesartan.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Irbesartan.Approved, Investigational
BrofaromineBrofaromine may increase the hypotensive activities of Irbesartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Irbesartan.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Irbesartan.Approved
BucillamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Irbesartan.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Irbesartan.Approved, Investigational
BupranololIrbesartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Irbesartan.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Irbesartan.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Irbesartan.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Irbesartan.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Irbesartan.Approved
CadralazineCadralazine may increase the hypotensive activities of Irbesartan.Experimental
CafedrineIrbesartan may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Irbesartan.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Irbesartan.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Irbesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Irbesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Irbesartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Irbesartan can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Irbesartan.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Irbesartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Irbesartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Irbesartan.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Irbesartan.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Irbesartan.Approved, Investigational
CeliprololIrbesartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Irbesartan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Irbesartan.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Irbesartan.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Irbesartan.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Irbesartan.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Irbesartan.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Irbesartan.Approved
CholecalciferolThe metabolism of Irbesartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Choline magnesium trisalicylate.Approved
CicletanineIrbesartan may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Irbesartan.Approved, Investigational
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Irbesartan.Approved, Investigational
CiprofloxacinIrbesartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Irbesartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Irbesartan.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Irbesartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clonixin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Irbesartan.Approved, Nutraceutical
CloranololIrbesartan may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Irbesartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Irbesartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Irbesartan.Approved, Investigational
CrisaboroleThe metabolism of Irbesartan can be decreased when combined with Crisaborole.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Irbesartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Irbesartan is combined with Curcumin.Investigational
CyclopenthiazideIrbesartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.Approved, Investigational
CyclosporineIrbesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Irbesartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Irbesartan is combined with D-Limonene.Investigational
DabrafenibThe serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Irbesartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Irbesartan.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Irbesartan.Approved, Investigational
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Irbesartan.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Irbesartan.Approved, Investigational
DeferasiroxThe serum concentration of Irbesartan can be increased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Delapril.Experimental
DelavirdineThe metabolism of Irbesartan can be decreased when combined with Delavirdine.Approved
DeserpidineIrbesartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Irbesartan.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Irbesartan.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Irbesartan.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Irbesartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Irbesartan.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Irbesartan.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Irbesartan.Approved
diethylnorspermineIrbesartan may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Irbesartan.Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Irbesartan.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Irbesartan.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Irbesartan.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Irbesartan.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Irbesartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Irbesartan.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Irbesartan.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Irbesartan.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Irbesartan.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Irbesartan.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Irbesartan.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Irbesartan.Approved
DosulepinThe metabolism of Irbesartan can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Irbesartan.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Irbesartan.Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Irbesartan.Approved, Illicit
DrospirenoneIrbesartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam.Approved
DuloxetineIrbesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Irbesartan is combined with E-6201.Investigational
EfavirenzThe metabolism of Irbesartan can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineIrbesartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Irbesartan.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Irbesartan.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Irbesartan.Approved
EndralazineEndralazine may increase the hypotensive activities of Irbesartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Irbesartan.Approved
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Irbesartan.Approved
EpanololIrbesartan may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Irbesartan.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Irbesartan.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Irbesartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Irbesartan.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Irbesartan.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Irbesartan.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Irbesartan.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Irbesartan.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Irbesartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ethenzamide.Experimental
EtodolacThe metabolism of Etodolac can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Irbesartan.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Irbesartan.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Irbesartan is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Irbesartan.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Irbesartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Feprazone.Experimental
Ferulic acidIrbesartan may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Irbesartan.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Irbesartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Irbesartan can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Irbesartan.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Irbesartan.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Irbesartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Irbesartan.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Irbesartan.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Irbesartan.Approved
FluvoxamineThe metabolism of Irbesartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Irbesartan.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Irbesartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Irbesartan.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Irbesartan.Approved, Vet Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Irbesartan.Investigational
GemfibrozilThe metabolism of Irbesartan can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Irbesartan.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Irbesartan.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Irbesartan.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Irbesartan.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Irbesartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Irbesartan.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Irbesartan.Approved
GuanazodineIrbesartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineIrbesartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Irbesartan.Approved, Investigational
GuanoclorIrbesartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIrbesartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIrbesartan may increase the hypotensive activities of Guanoxan.Experimental
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Irbesartan.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Irbesartan.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Irbesartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Irbesartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
HexamethoniumIrbesartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Irbesartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Higenamine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Irbesartan.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Irbesartan.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Irbesartan.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Irbesartan.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Irbesartan.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Irbesartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Irbesartan is combined with Icatibant.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Irbesartan.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Irbesartan.Approved
IloprostIloprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Irbesartan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Irbesartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Irbesartan.Approved
IndenololIrbesartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Irbesartan can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Irbesartan.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indobufen.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Irbesartan.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Irbesartan.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Irbesartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Irbesartan.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Irbesartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Irbesartan.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Irbesartan.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Irbesartan.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Irbesartan.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Irbesartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Kebuzone.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Irbesartan.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Irbesartan.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Irbesartan.Approved, Investigational
KetoconazoleThe metabolism of Irbesartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Irbesartan.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Irbesartan.Approved
LacidipineIrbesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Irbesartan.Approved, Investigational
LapatinibThe metabolism of Irbesartan can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Irbesartan.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Irbesartan.Approved
LevobunololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Irbesartan.Approved, Investigational
LevodopaIrbesartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Irbesartan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Irbesartan.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Irbesartan.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Irbesartan.Approved, Vet Approved
LinsidomineIrbesartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisofylline.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Irbesartan.Approved, Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Irbesartan.Approved
LobeglitazoneThe metabolism of Irbesartan can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineIrbesartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lonazolac.Experimental
LoperamideThe metabolism of Loperamide can be decreased when combined with Irbesartan.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Irbesartan.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Irbesartan.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Irbesartan.Approved
LovastatinThe metabolism of Irbesartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Irbesartan can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Irbesartan.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Irbesartan.Illicit, Investigational, Withdrawn
MacitentanIrbesartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate.Approved
ManidipineIrbesartan may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Irbesartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Irbesartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Irbesartan.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Irbesartan.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Irbesartan.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Irbesartan.Investigational, Withdrawn
MesalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Irbesartan.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Irbesartan.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Irbesartan.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Irbesartan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Irbesartan.Approved
MethoserpidineIrbesartan may increase the hypotensive activities of Methoserpidine.Experimental
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Irbesartan.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Irbesartan.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Irbesartan.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Irbesartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Irbesartan.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Irbesartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Irbesartan.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Irbesartan.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Irbesartan.Approved
MetyrosineIrbesartan may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Irbesartan.Experimental
MibefradilIrbesartan may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidostaurinThe metabolism of Irbesartan can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Irbesartan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Irbesartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Irbesartan.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Irbesartan.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Irbesartan.Approved
MizoribineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Irbesartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Irbesartan.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Irbesartan.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Irbesartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Irbesartan.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Irbesartan.Investigational
MuzolimineIrbesartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Irbesartan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Irbesartan.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Irbesartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Naftifine.Approved
NaftopidilIrbesartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxoneThe metabolism of Naloxone can be decreased when combined with Irbesartan.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Irbesartan.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Irbesartan.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Irbesartan.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Irbesartan.Approved
NialamideNialamide may increase the hypotensive activities of Irbesartan.Withdrawn
NicardipineThe metabolism of Irbesartan can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Irbesartan.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Irbesartan.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Irbesartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Niflumic Acid.Approved
NiguldipineIrbesartan may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Irbesartan can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineIrbesartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Irbesartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Irbesartan.Approved
NitrendipineIrbesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Irbesartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Irbesartan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Irbesartan.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Irbesartan.Approved
ObinutuzumabIrbesartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Irbesartan.Withdrawn
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Irbesartan.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Irbesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Irbesartan.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Omapatrilat.Investigational
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Irbesartan.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Irbesartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Orgotein.Vet Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Irbesartan.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Irbesartan.Approved
OxprenololIrbesartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Irbesartan.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Irbesartan.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Irbesartan.Approved
PargylinePargyline may increase the hypotensive activities of Irbesartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Parthenolide.Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Irbesartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Irbesartan.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
PentoliniumIrbesartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Irbesartan.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Irbesartan.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Irbesartan.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Irbesartan.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Irbesartan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Irbesartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Irbesartan.Withdrawn
PhenobarbitalThe metabolism of Irbesartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Irbesartan.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Irbesartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Irbesartan.Approved, Investigational
PhentolaminePhentolamine may increase the hypotensive activities of Irbesartan.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Irbesartan.Approved, Vet Approved
PhenytoinThe metabolism of Irbesartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Irbesartan.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Irbesartan.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Irbesartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Irbesartan.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Irbesartan.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Irbesartan.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pirprofen.Experimental
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Irbesartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Irbesartan.Withdrawn
Platelet Activating FactorIrbesartan may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideIrbesartan may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Irbesartan.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Irbesartan.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pranoprofen.Experimental, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Irbesartan.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Irbesartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Irbesartan.Approved
PrimidoneThe metabolism of Irbesartan can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Irbesartan.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Irbesartan.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Proglumetacin.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Irbesartan.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Irbesartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Propacetamol.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Irbesartan.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Irbesartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Irbesartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Irbesartan.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Irbesartan.Approved
QuinineQuinine may increase the hypotensive activities of Irbesartan.Approved
RabeprazoleThe metabolism of Irbesartan can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Irbesartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Irbesartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Irbesartan.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Irbesartan.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Irbesartan.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
RifampicinThe metabolism of Irbesartan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Irbesartan can be increased when combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Irbesartan.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Riociguat.Approved
RisperidoneIrbesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabIrbesartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Irbesartan.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Irbesartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Irbesartan.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Irbesartan.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Irbesartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Irbesartan.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Irbesartan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Irbesartan.Approved
SafrazineSafrazine may increase the hypotensive activities of Irbesartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Irbesartan.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salsalate.Approved
SaprisartanIrbesartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe metabolism of Irbesartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Irbesartan.Approved
SemapimodThe risk or severity of adverse effects can be increased when Irbesartan is combined with Semapimod.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Irbesartan.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Irbesartan is combined with Serrapeptase.Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Irbesartan.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Irbesartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Irbesartan.Approved
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Irbesartan.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Irbesartan.Approved
Sodium phosphateIrbesartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SorafenibThe metabolism of Irbesartan can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Irbesartan.Approved
SRT501The risk or severity of adverse effects can be increased when Irbesartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Irbesartan.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Irbesartan.Approved, Investigational
SulfadiazineThe metabolism of Irbesartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Irbesartan can be decreased when combined with Sulfamethoxazole.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Irbesartan.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Irbesartan.Approved
SulfisoxazoleThe metabolism of Irbesartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulindac.Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Irbesartan.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
TalinololIrbesartan may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Irbesartan.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Irbesartan.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Irbesartan.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tarenflurbil.Investigational
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Irbesartan.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Irbesartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Irbesartan.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tenidap.Experimental
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Irbesartan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Irbesartan.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Irbesartan.Experimental
TeriflunomideThe metabolism of Irbesartan can be decreased when combined with Teriflunomide.Approved
TerlipressinIrbesartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Irbesartan.Approved, Investigational
TetrahydropalmatineIrbesartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
TheodrenalineIrbesartan may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Irbesartan.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Irbesartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Irbesartan.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tiaprofenic acid.Approved
TiboloneIrbesartan may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Irbesartan can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Irbesartan can be decreased when combined with Ticlopidine.Approved
TicrynafenIrbesartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Irbesartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Irbesartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
TolbutamideThe metabolism of Irbesartan can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Irbesartan.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolmetin.Approved
TolonidineIrbesartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Irbesartan.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Irbesartan.Approved, Investigational
TolvaptanTolvaptan may increase the hyperkalemic activities of Irbesartan.Approved
TopiroxostatThe metabolism of Irbesartan can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Irbesartan.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Irbesartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Irbesartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Irbesartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Irbesartan.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Irbesartan.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Irbesartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Irbesartan.Approved
TribenosideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Irbesartan.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Irbesartan.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Irbesartan.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Irbesartan.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Irbesartan.Approved
TriptolideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Triptolide.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Irbesartan.Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Irbesartan.Approved, Experimental
UdenafilUdenafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
UnoprostoneIrbesartan may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Irbesartan.Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Irbesartan.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Irbesartan.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Irbesartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Irbesartan.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Irbesartan.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Irbesartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Irbesartan.Investigational
VincamineIrbesartan may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIrbesartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Irbesartan.Approved
VoriconazoleThe metabolism of Irbesartan can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Irbesartan.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Irbesartan.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Irbesartan.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
XipamideIrbesartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineIrbesartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Irbesartan.Approved, Vet Approved
ZafirlukastThe metabolism of Irbesartan can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Irbesartan.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Irbesartan.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Irbesartan.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Irbesartan.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zomepirac.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Irbesartan.Approved
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Gennady Nisnevich, "Novel synthesis of irbesartan." U.S. Patent US20040192713, issued September 30, 2004.

US20040192713
General References
  1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. [PubMed:11565517]
  2. Adams MA, Trudeau L: Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol. 2000 Spring;7(1):22-31. [PubMed:10822210]
  3. Croom KF, Curran MP, Goa KL, Perry CM: Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028. [PubMed:15101793]
External Links
Human Metabolome Database
HMDB15163
KEGG Drug
D00523
KEGG Compound
C07469
PubChem Compound
3749
PubChem Substance
46506575
ChemSpider
3618
BindingDB
50042235
ChEBI
5959
ChEMBL
CHEMBL1513
Therapeutic Targets Database
DAP000364
PharmGKB
PA450084
IUPHAR
589
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Irbesartan
ATC Codes
C09DB05 — Irbesartan and amlodipineC09DA04 — Irbesartan and diureticsC09CA04 — Irbesartan
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
FDA label
Download (263 KB)
MSDS
Download (57.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentDiabetic Kidney Disease1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1, 2Not Yet RecruitingTreatmentEbola Virus Disease1
2Active Not RecruitingTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentChronic Kidney Disease (CKD)1
2CompletedTreatmentHypertensive2
2RecruitingTreatmentBlood Pressures / BMI >30 kg/m2 / Hypertensive / Stress, Psychological1
2, 3CompletedPreventionDiabetic Nephropathies / Glomerulonephritis / Kidney Diseases / Proteinuria1
2, 3CompletedTreatmentHypertensive1
3Active Not RecruitingTreatmentIgA Nephropathy1
3Active Not RecruitingTreatmentTransplantation, Kidney1
3CompletedPreventionCardiovascular Disease (CVD) / Nonvalvular Atrial Fibrillation1
3CompletedPreventionKidney Failure,Chronic1
3CompletedTreatmentChronic Allograft Nephropathy (CAN) / End-Stage Renal Disease (ESRD)1
3CompletedTreatmentCongestive Heart Failure (CHF)1
3CompletedTreatmentHepatitis C, Chronic1
3CompletedTreatmentHypercholesterolaemia1
3CompletedTreatmentHyperlipidemias / Hypertensive1
3CompletedTreatmentHypertensive8
3CompletedTreatmentHypertensive / Microalbuminuria / Type 2 Diabetes Mellitus1
3CompletedTreatmentHypertensive / Myocardial Ischemia1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3RecruitingTreatmentEhlers-Danlos Syndrome, Vascular Type1
3Unknown StatusPreventionHypertensive / Nonvalvular Atrial Fibrillation1
3Unknown StatusTreatmentSevere Sepsis1
4Active Not RecruitingTreatmentDiabetes / Hypertensive Disease1
4CompletedNot AvailableType 2 Diabetes Mellitus1
4CompletedPreventionHypertensive1
4CompletedTreatmentAlbuminuria1
4CompletedTreatmentChronic Heart Failure (CHF)1
4CompletedTreatmentDyslipidemias / Hypertensive1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHypertensive15
4CompletedTreatmentHypertensive / Metabolic Syndromes1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentMicroalbuminuria / Type 2 Diabetes Mellitus1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentType 2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetic Nephropathy1
4SuspendedTreatmentMyocardial Infarction (MI)1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentAntihypertensive Drugs / Diastolic Function / Hypertensive Heart Disease / Left Atrial Volume / Renin Angiotensin System1
4Unknown StatusTreatmentHypertensive / Obesity, Abdominal1
4Unknown StatusTreatmentHypertensive / Sexual Dysfunctions1
4Unknown StatusTreatmentPersistent Atrial Fibrillation1
4WithdrawnDiagnosticBMI >30 kg/m2 / Hypertensive1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedEducational/Counseling/TrainingHealthy Volunteers1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentHypertensive4
Not AvailableRecruitingNot AvailableChronic Kidney Disease (CKD)1
Not AvailableRecruitingScreeningPreeclampsia / Pregnancy associated hypertension1
Not AvailableRecruitingTreatmentObesity and Glomerulopathy1
Not AvailableTerminatedTreatmentMetabolic Syndromes1
Not AvailableUnknown StatusBasic ScienceHypertensive / Insulin Resistance / Microcirculation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral150 mg/1
TabletOral150 mg
TabletOral300 mg/1
TabletOral300 mg
TabletOral75 mg
TabletOral150 mg/150mg
TabletOral300 mg/300mg
TabletOral75 mg/75mg
TabletOral75 mg/1
Tablet, coatedOral150 mg/1
Tablet, coatedOral300 mg/1
Tablet, coatedOral75 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral75 mg/1
TabletOral
Tablet, film coatedOral
Tablet, film coatedOral150 mg
Tablet, film coatedOral300 mg
Tablet, film coatedOral75 mg
Prices
Unit descriptionCostUnit
Avalide 300-25 mg tablet3.92USD tablet
Avalide 300-12.5 mg tablet3.63USD tablet
Avalide 150-12.5 mg tablet3.33USD tablet
Avapro 300 mg tablet2.64USD tablet
Avapro 150 mg tablet2.33USD tablet
Avapro 75 mg tablet2.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5270317No1994-09-302011-09-30Us
CA2177772No2007-04-102016-05-30Canada
CA2057913No1997-07-082011-03-20Canada
US6342247Yes1995-12-072015-12-07Us
US5994348Yes1995-12-072015-12-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)180-181 °CNot Available
logP6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00884 mg/mLALOGPS
logP4.51ALOGPS
logP5.5ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.13 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity136.72 m3·mol-1ChemAxon
Polarizability47.59 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9271
Caco-2 permeable-0.5679
P-glycoprotein substrateSubstrate0.7046
P-glycoprotein inhibitor IInhibitor0.639
P-glycoprotein inhibitor IINon-inhibitor0.6458
Renal organic cation transporterNon-inhibitor0.5091
CYP450 2C9 substrateNon-substrate0.6401
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5749
CYP450 1A2 substrateNon-inhibitor0.6782
CYP450 2C9 inhibitorInhibitor0.5928
CYP450 2D6 inhibitorNon-inhibitor0.7584
CYP450 2C19 inhibitorInhibitor0.6619
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6192
Ames testNon AMES toxic0.5238
CarcinogenicityNon-carcinogens0.7492
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7762 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9171
hERG inhibition (predictor II)Non-inhibitor0.7728
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-0000900000-b6619e18dca63147588d
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004l-0801900000-b884691a3577ffab749f
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0006-0900000000-130056acf88b6caed131
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0006-0900000000-97919ed4377a869dc8cc
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0006-0900000000-55cf0ae2c686af5c38e3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0007-0908000000-0c994ee86857e7d63e48
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0000900000-b610a12a9852ff1a11c1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900100000-c9024d0b00a0ec781fa2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-cb54b7c0917d67313110
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-4e0d1ebbc0609ecaa59d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-ec0fc575bb22a99c258d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0900000000-f1f0658a24e5097674e0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0000900000-12da76073bae1768b7e2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-cce4e6a8c5bbaa66c902
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-c7202e4de31fc762cf2d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-ad31324f1b1a0e9be0b8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-2301c02c521c3dab9c79
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0900000000-8b6e9e772c5af1365e87
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0007-0908000000-97706153fba817a654e4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-002f-0900400000-f9f11306595c7a9de207
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a6r-0180900000-009718baea4be3419b76
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0190000000-97e745948e54828d3cb9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0190000000-da94b482f79a90e5784c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0590000000-122d562d8d5352dd2a88
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0290100000-e3c8e0950f0290ccefdc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0000900000-61da6c552b6d170d8283
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0290100000-0e7bf8c50467ae6a7604
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0290000000-21c875faccf2cb3a15b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0490000000-e7c75f4866b7b9f0d0e8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a59-1960000000-a6601ea10b0fe87e6c0a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a5c-0920000000-d7f5d3920f8586eac33f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0000900000-57215a52cacf3c9ede5c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0290100000-29a34a51d9b42976905f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0290000000-e6e7f5d1e696ec43651d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1690000000-217de4040066a20fd367
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a59-1950000000-ac722925e6b2aa2930fb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a5c-0930000000-0b8d8a97e3db30de0e21
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0290100000-ee3d21bc8110bf939cdd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a59-2791700000-a5bc1c8b020f7731fb1e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-056r-0361900000-10d459e7561fdaacc9d4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a6r-0490500000-2693358cc0b819b773a5

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / Alpha amino acids and derivatives / Imidazolinones / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Biphenyl / Phenyltetrazole / Alpha-amino acid or derivatives / Imidazolinone / Azole / 2-imidazoline / Heteroaromatic compound / Tetrazole / Amidine / Carboxylic acid amidine
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
azaspiro compound, biphenylyltetrazole (CHEBI:5959)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Voigt JP, Bramlage P, Fink H: Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats. Eur J Pharmacol. 2007 Jun 14;564(1-3):131-7. Epub 2007 Mar 3. [PubMed:17408613]
  3. Waeber B, Burnier M: AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Expert Rev Cardiovasc Ther. 2003 May;1(1):23-33. [PubMed:15030294]
  4. Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D, Bidouard JP, Janiak P, Schaeffer P, Herbert JM: Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2001 Sep;38(3):395-405. [PubMed:11486244]
  5. Martin G, Dol F, Mares AM, Berezowski V, Staels B, Hum DW, Schaeffer P, Herbert JM: Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol. 2004 Feb;43(2):191-9. [PubMed:14716205]
  6. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In 't Veld AJ, et al.: Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension. 1995 Jan;25(1):22-9. [PubMed:7843749]
  7. Carraway JW, Park S, McCune SA, Holycross BJ, Radin MJ: Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. J Cardiovasc Pharmacol. 1999 Mar;33(3):451-60. [PubMed:10069682]
  8. Hope S, Brecher P, Chobanian AV: Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999 Jan;12(1 Pt 1):28-34. [PubMed:10075381]
  9. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M: Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999 Mar;33(3):850-5. [PubMed:10082498]
  10. Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjoquist PO, Abrahamsson T: Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension. 1999 Jun;33(6):1406-13. [PubMed:10373224]
  11. Adams MA, Trudeau L: Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol. 2000 Spring;7(1):22-31. [PubMed:10822210]
  12. Croom KF, Plosker GL: Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs. 2008;68(11):1543-69. [PubMed:18627212]
  13. Croom KF, Curran MP, Goa KL, Perry CM: Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028. [PubMed:15101793]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expre...
Gene Name
JUN
Uniprot ID
P05412
Uniprot Name
Transcription factor AP-1
Molecular Weight
35675.32 Da
References
  1. Zhu ZS, Wang JM, Chen SL: Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats. World J Gastroenterol. 2004 May 15;10(10):1471-5. [PubMed:15133856]
  2. Cheng SM, Yang SP, Ho LJ, Tsao TP, Chang DM, Lai JH: Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1. Br J Pharmacol. 2004 Jul;142(6):933-42. Epub 2004 Jun 21. [PubMed:15210574]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34